Payandeh Mehrdad, Zamanian Mohammad Hossein, Nomanpour Bizhan, Farhadi Mohammad Soroush, Janbakhsh Alireza, Rostamian Mosayeb, Elahi Azam, Jafari Somayeh, Dehghannejad Mohammad
Hematology and Medical Oncology Dept., Kermanshah University of Medical Sciences, Kermanshah, Iran.
Infectious Diseases Dept., School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Infect Agent Cancer. 2021 Feb 2;16(1):8. doi: 10.1186/s13027-021-00349-4.
Human Cytomegalovirus (HCMV) is the most important viral pathogen in people undergoing bone marrow transplantation (BMT). HCMV detection in the early stages makes is possible to save the patients' lives through immediate and timely treatment. The aim of this study was to investigate the status of HCMV using the real-time PCR method in BMT patients in Kermanshah, west of Iran.
HCMV monitoring was done in 120 patients who underwent BMT, 38 allogeneic cases and 82 autologous cases, using the ELISA serology test before transplantation. The participants were followed up 100 days after transplantation for HCMV detection in blood samples using real-time PCR. Preemptive therapy started with Ganciclovir and Foscarnet when the viral load was > 200 HCMV DNA copies/ml.
Despite preemptive therapy, infection recurred in less than 1 month. HCMV recurred more frequently in patients undergoing allogenic transplation versus those receiving autologous transplantation. Recurrence was seen in 5 patients receiving allogenic transplantation. HCMV recurrence occurred in five patients with allogeneic transplantation. Twelve patients undergoing allogeneic or autologous transplantation (83%) and a virus load of > 1000 copies/ml showed HCMV-related symptoms. Three patients died, two due to HCMV-related pneumonia and the other one due to a fungal infection.
Real-time PCR may be a useful method for quantification and monitoring of HCMV recurrence and may be helpful in choosing more efficient HCMV preemptive treatment in BMT recipients.
人巨细胞病毒(HCMV)是接受骨髓移植(BMT)患者中最重要的病毒病原体。早期检测HCMV使得通过及时有效的治疗挽救患者生命成为可能。本研究旨在利用实时荧光定量PCR方法调查伊朗西部克尔曼沙赫BMT患者中HCMV的感染状况。
对120例接受BMT的患者进行HCMV监测,其中38例为同种异体移植病例,82例为自体移植病例,移植前采用ELISA血清学检测。移植后100天对参与者进行随访,采用实时荧光定量PCR检测血样中的HCMV。当病毒载量>200 HCMV DNA拷贝/ml时,开始使用更昔洛韦和膦甲酸钠进行抢先治疗。
尽管进行了抢先治疗,但感染仍在不到1个月内复发。与自体移植患者相比,同种异体移植患者中HCMV复发更为频繁。5例接受同种异体移植的患者出现复发。12例接受同种异体或自体移植(83%)且病毒载量>1000拷贝/ml的患者出现HCMV相关症状。3例患者死亡,2例死于HCMV相关肺炎,另1例死于真菌感染。
实时荧光定量PCR可能是定量和监测HCMV复发的有用方法,可能有助于为BMT受者选择更有效的HCMV抢先治疗方案。